Optimist Retirement Group LLC Has $599,000 Stock Holdings in Organon & Co. (NYSE:OGN)

Optimist Retirement Group LLC reduced its holdings in Organon & Co. (NYSE:OGN) by 61.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 40,165 shares of the company’s stock after selling 63,000 shares during the quarter. Optimist Retirement Group LLC’s holdings in Organon & Co. were worth $599,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. Prospera Private Wealth LLC acquired a new stake in Organon & Co. in the third quarter valued at $25,000. Horizon Bancorp Inc. IN grew its position in shares of Organon & Co. by 2,401.5% in the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after buying an additional 1,585 shares during the last quarter. Abich Financial Wealth Management LLC increased its stake in shares of Organon & Co. by 5,646.3% in the third quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock valued at $45,000 after buying an additional 2,315 shares during the period. Trust Co. of Vermont raised its position in shares of Organon & Co. by 109.4% during the third quarter. Trust Co. of Vermont now owns 2,626 shares of the company’s stock worth $50,000 after acquiring an additional 1,372 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its position in shares of Organon & Co. by 32.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after acquiring an additional 672 shares during the last quarter. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Performance

Shares of Organon & Co. stock opened at $15.32 on Thursday. The business has a 50-day moving average price of $15.41 and a two-hundred day moving average price of $17.79. Organon & Co. has a 1-year low of $13.87 and a 1-year high of $23.10. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The company has a market cap of $3.94 billion, a P/E ratio of 3.04, a PEG ratio of 0.87 and a beta of 0.76.

Wall Street Analysts Forecast Growth

Separately, TD Cowen upgraded Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Organon & Co. has an average rating of “Hold” and a consensus target price of $21.33.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.